These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
5. [Complement activation in patients with chronic polyarthritis, measured by the level of complement fraction C3a in plasma]. Kapp A; Meske-Brand S; Maly FE; Müller W Z Rheumatol; 1984; 43(3):103-5. PubMed ID: 6332437 [TBL] [Abstract][Full Text] [Related]
6. Capnocytophaga infection: a risk in the immunocompromised host. Rummens JL; Verfaillie C; Louwagie A; Boelaert J; Van Landuyt HW Acta Clin Belg; 1984; 39(2):109-13. PubMed ID: 6741389 [No Abstract] [Full Text] [Related]
8. Increased anaphylatoxins (C3a and C4a) in psoriatic sera. Ohkohchi K; Takematsu H; Tagami H Br J Dermatol; 1985 Aug; 113(2):189-96. PubMed ID: 3875363 [TBL] [Abstract][Full Text] [Related]
9. Modulation of in vitro human lymphocyte responses by an exopolysaccharide from Capnocytophaga ochracea. Bolton RW; Dyer JK; Reinhardt RA; Okano DK J Dent Res; 1983 Dec; 62(12):1186-9. PubMed ID: 6581194 [TBL] [Abstract][Full Text] [Related]
10. Angiography and complement activation. Evidence for generation of C3a anaphylatoxin by intravascular contrast agents. Westaby S; Dawson P; Turner MW; Pridie RB Cardiovasc Res; 1985 Feb; 19(2):85-8. PubMed ID: 3872180 [TBL] [Abstract][Full Text] [Related]
11. Inhibition of cleavage of the third component of human complement (C3) by its small cleavage fragment, C3a: inhibition occurs with the classical-pathway, but not the alternative-pathway, C3 convertase. Strunk RC; Webster RO Mol Immunol; 1985 Jan; 22(1):37-43. PubMed ID: 3871899 [TBL] [Abstract][Full Text] [Related]
12. Isolation and partial characterization of a genus common antigen and species specific antigen of Capnocytophaga. Murayama Y; Mashimo PA; Tabak LA; Levine MJ; Ellison SA Jpn J Med Sci Biol; 1982 Aug; 35(4):153-70. PubMed ID: 6185710 [TBL] [Abstract][Full Text] [Related]
13. Complement activation produced by biomaterials. Chenoweth DE Artif Organs; 1988 Dec; 12(6):508-10. PubMed ID: 3265053 [TBL] [Abstract][Full Text] [Related]
14. Complement activation during systemic lupus erythematosus. C3a and C5a anaphylatoxins circulate during exacerbations of disease. Belmont HM; Hopkins P; Edelson HS; Kaplan HB; Ludewig R; Weissmann G; Abramson S Arthritis Rheum; 1986 Sep; 29(9):1085-9. PubMed ID: 3489467 [TBL] [Abstract][Full Text] [Related]
15. Complement C3 cleavage and cytokines interleukin-1beta and tumor necrosis factor-alpha in otitis media with effusion. Närkiö-Mäkelä M; Teppo AM; Meri S Laryngoscope; 2000 Oct; 110(10 Pt 1):1745-9. PubMed ID: 11037838 [TBL] [Abstract][Full Text] [Related]
16. Complement activation and generation of C3a anaphylatoxin by radiological contrast agents. Dawson P; Turner MW; Bradshaw A; Westaby S Br J Radiol; 1983 Jul; 56(667):447-8. PubMed ID: 6602640 [TBL] [Abstract][Full Text] [Related]
17. Leukocyte aggregation response to quantitative plasma levels of C3a and C5a. Williams JJ; Yellin SA; Slotman GJ Arch Surg; 1986 Mar; 121(3):305-7. PubMed ID: 3484946 [TBL] [Abstract][Full Text] [Related]
18. Effects of complement activation by hemodialysis membranes. Cheung AK; Henderson LW Am J Nephrol; 1986; 6(2):81-91. PubMed ID: 3518458 [No Abstract] [Full Text] [Related]
20. Use of adhesin-specific monoclonal antibodies to identify and localize an adhesin on the surface of Capnocytophaga gingivalis DR2001. Tempro P; Cassels F; Siraganian R; Hand AR; London J Infect Immun; 1989 Nov; 57(11):3418-24. PubMed ID: 2572552 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]